Lv2
140 积分 2021-03-11 加入
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma
12天前
已完结
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma
12天前
已完结
Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints
25天前
已完结
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study
3个月前
已完结
Toxicity and response criteria of the Eastern Cooperative Oncology Group
3个月前
已完结
A Novel Anti-CD38 Monoclonal Antibody for Treating Immune Thrombocytopenia
3个月前
已完结
CD19 CAR T-Cell Therapy in Autoimmune Disease — A Case Series with Follow-up
3个月前
已完结
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
3个月前
已完结
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
4个月前
已完结
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
4个月前
已完结
皖公网安备34019202002308
